Radiopharmaceuticals

Uptodate 2015


Bone-targeting radioisotopes (eg, strontium-89 [89Sr], samarium-153 lexidronam [153Sm], radium-223) localize to areas of osteoblastic activity, and are indicated for the treatment of bone pain in patients with predominantly osteoblastic metastases. Because these agents are systemically administered, they are most appropriate for patients with multiple painful lesions.

0